Skip to main content

Month: August 2023

Esperion Presents Two CLEAR Outcomes Study Late-Breakers at European Society of Cardiology Congress 2023

– In total cardiovascular event analysis, bempedoic acid shows 20% risk reduction in MACE-4 and 17% risk reduction in MACE-3 – – In an analysis of patients with diabetes, bempedoic acid shows 17% risk reduction in MACE-4 and 20% risk reduction in MACE-3 – – No increase in development of new onset diabetes in patients randomized to bempedoic acid compared to placebo – ANN ARBOR, Mich., Aug. 26, 2023 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced the presentation of results from two oral presentations at the Late-Breaking Science Session entitled, “Clinical trial updates on prevention and lipid lowering” at the European Society of Cardiology (ESC) 2023 Congress, taking place August 25-28, 2023, in Amsterdam, Netherlands. “We are pleased to share additional results from our landmark CLEAR Outcomes study in late-breaker...

Continue reading

NNIT A/S: NNIT lifts 2023 outlook and presents preliminary Q2 and H1 2023 financial figures

Following improved business performance in Q2 and H1 2023, NNIT upgrades the full-year outlook and now expects to generate revenue growth of around 15% and an operating profit margin before special items of around 6% in 2023 against the previous expectations for revenue growth around 10% and an operating profit margin before special items of around 5%. Special items are still expected to amount to up to DKK 70 million in 2023. According to preliminary and unaudited financial figures, group revenue grew by 15% to DKK 424 million (2022: DKK 368 million) in Q2 2023 and by 16% to DKK 837 million (2022: DKK 724 million) in H1 2023. The group’s operating profit before special items increased to DKK 25 million (2022: DKK -18 million) in Q2 2023 and DKK 45 million (2022: DKK -34 million) in H1 2023, corresponding to an operating profit margin...

Continue reading

Mandatory notification of trade in Vistin Pharma ASA

Ferncliff Listed DAI AS has on 25 August 2023 purchased 200,000 shares in Vistin Pharma ASA at NOK 21 per share. After the transaction Ferncliff Listed DAI AS has a holding of 1,234,280 shares, corresponding to 2,78% ownership. Ferncliff Listed DAI AS is closely associated with board member Øystein Stray Spetalen.Attachment20230825_Notification of trade_Ferncliff i Vistin

Continue reading

Prairie Provident Resources Announces Second Quarter 2023 Financial and Operating Results

CALGARY, Alberta, Aug. 25, 2023 (GLOBE NEWSWIRE) — Prairie Provident Resources Inc. (“Prairie Provident”, “PPR” or the “Company”) announces our operating and financial results for the quarter ended June 30, 2023. PPR’s interim financial statements and related Management’s Discussion and Analysis (MD&A) are available on our website at www.ppr.ca and filed on SEDAR at www.sedar.com. MESSAGE TO SHAREHOLDERS Patrick McDonald, Interim President and CEO commented: “With the May 2023 completion of the Company’s recapitalization transactions, Prairie Provident is positioned to focus on the creation of and unlocking of value which exists within the company’s asset base. The operations team has been able to maintain production levels through attention to production and maintenance activities and the...

Continue reading

FANHUA Unveils New Mission, New Vision alongside a Refreshed Corporate Logo and Announces Change of Domain Name for Its IR Website

Fanhua Before and After LogoFanhua Before and After LogoGUANGZHOU, China, Aug. 25, 2023 (GLOBE NEWSWIRE) — FANHUA Inc. (“Fanhua” or “the Company”) (Nasdaq: FANH), a leading independent financial services provider in China, today unveils its new mission statement, vision, corporate values alongside a refreshed corporate logo. As Fanhua embrace new opportunities in the new era, FANHUA envisions itself as a globally leading technology-driven financial service platform, and sets a new mission to empower financial advisors and drive continuous value creation for customers. Mr. Yinan Hu, Co-chairman and CEO of FANHUA commented: “As the Company approaches the key milestone of its 25th anniversary, we are officially unveiling a new mission, a new vision, and new values. These are intended to solidify as a roadmap, guiding everyone...

Continue reading

BULGOLD Announces Filing of Second Quarter Financial Results for Six and Three Months Ended June 30, 2023

TORONTO, Aug. 25, 2023 (GLOBE NEWSWIRE) — BULGOLD Inc. (TSXV: ZLTO) (the “Company” or “BULGOLD”) is pleased to announce that it has filed its unaudited condensed interim financial statements and MD&A for the second quarter ended June 30, 2023. During the three months ended June 30, 2023, the Company incurred a net loss of $378,913 ($0.04 per share). For the six months ending June 30, 2023, the company incurred a net loss of $1,182,914 ($0.11 per share), including a non-cash expense of $734,269 being the cost of listing (the cost of listing relates to the recently completed acquisition of assets in Bulgaria). Other expenses incurred, primarily related to professional fees for the completion of the acquisition. On June 30, 2023, the company had cash (and cash equivalents) of $2,667,261 (net working capital of $ 2,584,856) which...

Continue reading

Biomerica Reports Fiscal 2023 Year End Results

Revenues excluding Covid test sales increased 15% for fiscal 2023 vs fiscal 2022Successfully completed inFoods® IBS pilot program with one of the largest Gastrointestinal physician groups in the USinFoods IBS completes pre-launch phase; Veteran VP of sales and national accounts hired; On track for national launch by calendar Q1 2024IRVINE, Calif., Aug. 25, 2023 (GLOBE NEWSWIRE) — Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products, today reported its fiscal 2023 financial results. Net sales for the fiscal year ended May 31, 2023 were $5.3 million as compared to net sales of $18.9 million in fiscal 2022. Net loss was $7.1 million for fiscal 2023 compared to a net loss of $4.6 million for fiscal 2022. The decrease in sales for fiscal 2023 was related to the Company’s decrease in...

Continue reading

American Future Fuel Receives Drilling Permit to Begin Drill Confirmation of Historical Inferred Uranium Resource of 18.98 Million Pounds(i) at Cebolleta

Figure 1Known Uranium Deposits at the Cebolleta ProjectVANCOUVER, British Columbia, Aug. 25, 2023 (GLOBE NEWSWIRE) — American Future Fuel Corporation (CSE: AMPS; OTCQB: AFFCF; FWB: K14, WKN: A3DQFB) (the “Company” or “American Future Fuel”), is pleased to announce the New Mexico Mining and Minerals Division has issued the Company its first drilling permit (the “permit”) at its 100% owned flagship Cebolleta Uranium Project (“Cebolleta” or the “Project”) located in the Grants Uranium Mineral Belt, 35 miles (56km) west of Albuquerque, New Mexico. Cebolleta is an advanced uranium exploration project with a historical uranium Inferred Mineral Resource of 5.6M tons (5.1M tonnes) at an average grade of 0.17% eU₃O₈ containing 18.98M lbs (8,600 tonnes) U₃O₈ according to a 2014 NI 43-101 Technical Report commissioned by previous...

Continue reading

Weekly Report (August 18-24, 2023) on the Second Tranche of Stellantis Share Buyback Program

Weekly Report (August 18–24, 2023) on the Second Tranche of Stellantis Share Buyback Program AMSTERDAM, August 25, 2023 – Stellantis N.V. (“Stellantis” or the “Company”) announced today that pursuant to its Second Tranche of the Share Buyback Program announced on June 7, 2023, covering up to €500 million to be executed in the open market during the period between June 7, 2023 and September 7, 2023, it has repurchased the following common shares in the period between August 18 up to and including August 24, 2023:Date Number of Shares Repurchased Average Market Purchase Price in € per share Repurchased Volume in € (excluding fees) Venues18/08/2023 635 788 €16.2285 €10 317 861 MILE18/08/2023 350 768 €16.2275 €5 692 099 CEUX18/08/2023 63 444 €16.2298 €1 029 681 TQEX21/08/2023 34 487 €16.5129 €569 479 MILE21/08/2023 6...

Continue reading

Live Oak Bank Names William C. (BJ) Losch, III as President

WILMINGTON, N.C., Aug. 25, 2023 (GLOBE NEWSWIRE) — Live Oak Bancshares (“Live Oak” or the “company”) announced today its Board of Directors has appointed William C. (BJ) Losch, III as President of Live Oak Bank effective today. Losch will continue to serve in his role as Chief Financial Officer of Live Oak Bancshares. Losch brings a wealth of experience and knowledge as Live Oak continues to expand its lending franchise, while launching new products and solutions to support its growing customer base. As CFO and Chief Banking Officer, Losch’s impact on company performance has exceeded expectations and he is well suited to take on this new leadership role for the company. “The Board and I are beyond excited to see BJ take on this role and lead Live Oak into the future. He has been instrumental in making numerous positive changes...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.